[1]
|
Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2012) The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. American Journal of Gastroenterology, 107, 811-826. https://doi.org/10.1038/ajg.2012.128
|
[2]
|
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Diabetologia, 59, 1121-1140. https://doi.org/10.1007/s00125-016-3902-y
|
[3]
|
Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M., et al. (2018) Mechanisms of NAFLD Development and Therapeutic Strategies. Nature Medicine, 24, 908-922. https://doi.org/10.1038/s41591-018-0104-9
|
[4]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. https://doi.org/10.1002/hep.28431
|
[5]
|
Freedberg, D.E., Kim, L.S. and Yang, Y.X. (2017) The Risks and Benefits of Long-Term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice from the American Gastroenterological Association. Gastroenterology, 152, 706-715. https://doi.org/10.1053/j.gastro.2017.01.031
|
[6]
|
Allin, K.H. and Moayyedi, P. (2021) Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander? Gastroenterology, 161, 1789-1791. https://doi.org/10.1053/j.gastro.2021.09.005
|
[7]
|
Hermos, J.A., Young, M.M., Fonda, J.R., et al. (2012) Risk of Community-Acquired Pneumonia in Veteran Patients to Whom Proton Pump Inhibitors Were Dispensed. Clinical Infectious Diseases, 54, 33-42. https://doi.org/10.1093/cid/cir767
|
[8]
|
Jandhyala, S.M., Talukdar, R., Subramanyam, C., et al. (2015) Role of the Normal Gut Microbiota. World Journal of Gastroenterology, 21, 8787-8803. https://doi.org/10.3748/wjg.v21.i29.8787
|
[9]
|
O’May, G.A., Reynolds, N., Smith, A.R., et al. (2005) Effect of pH and Antibiotics on Microbial Overgrowth in the Stomachs and Duodena of Patients Undergoing Percutaneous Endoscopic Gastrostomy Feeding. Journal of Clinical Microbiology, 43, 3059-3065. https://doi.org/10.1128/JCM.43.7.3059-3065.2005
|
[10]
|
Bruno, G., Zaccari, P., Rocco, G., et al. (2019) Proton Pump Inhibitors and Dysbiosis: Current Knowledge and Aspects to be Clarified. World Journal of Gastroenterology, 25, 2706-2719. https://doi.org/10.3748/wjg.v25.i22.2706
|
[11]
|
Lo, W.K. and Chan, W.W. (2013) Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 11, 483-490. https://doi.org/10.1016/j.cgh.2012.12.011
|
[12]
|
Jackson, M.A., Goodrich, J.K., Maxan, M.E., et al. (2016) Proton Pump Inhibitors Alter the Composition of the Gut Microbiota. Gut, 65, 749-756. https://doi.org/10.1136/gutjnl-2015-310861
|
[13]
|
Mishiro, T., Oka, K., Kuroki, Y., et al. (2018) Oral Microbiome Alterations of Healthy Volunteers with Proton Pump Inhibitor. Journal of Gastroenterology and Hepatology, 33, 1059-1066. https://doi.org/10.1111/jgh.14040
|
[14]
|
Imhann, F., Bonder, M.J., Vich Vila, A., et al. (2016) Proton Pump Inhibitors Affect the Gut Microbiome. Gut, 65, 740-748. https://doi.org/10.1136/gutjnl-2015-310376
|
[15]
|
Bouwknegt, M., Van Pelt, W., Kubbinga, M.E., et al. (2014) Potential Association between the Recent Increase in Campylobacteriosis Incidence in the Netherlands and Proton-Pump Inhibitor Use—An Ecological Study. Eurosurveillance, 19, Article 20873. https://doi.org/10.2807/1560-7917.ES2014.19.32.20873
|
[16]
|
Leonard, J., Marshall, J.K. and Moayyedi, P. (2007) Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression. The American Journal of Gastroenterology, 102, 2047-2056.
|
[17]
|
Janarthanan, S., Ditah, I., Adler, D.G., et al. (2012) Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis. The American Journal of Gastroenterology, 107, 1001-1010. https://doi.org/10.1038/ajg.2012.179
|
[18]
|
Imhann, F., Vich Vila, A., Bonder, M.J., et al. (2017) The Influence of Proton Pump Inhibitors and Other Commonly Used Medication on the Gut Microbiota. Gut Microbes, 8, 351-358. https://doi.org/10.1080/19490976.2017.1284732
|
[19]
|
Freedberg, D.E., Toussaint, N.C., Chen, S.P., et al. (2015) Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology, 149, 883-885. https://doi.org/10.1053/j.gastro.2015.06.043
|
[20]
|
Zhu, J., Sun, C., Li, M., et al. (2023) Compared to Histamine-2 Receptor Antagonist, Proton Pump Inhibitor Induces Stronger Oral-to-Gut Microbial Transmission and Gut Microbiome Alterations: A Randomised Controlled Trial. https://gut.bmj.com/content/early/2023/11/22/gutjnl-2023-330168 https://doi.org/10.1136/gutjnl-2023-330168
|
[21]
|
Chen, J. and Vitetta, L. (2020) Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. International Journal of Molecular Sciences, 21, Article 5214. https://doi.org/10.3390/ijms21155214
|
[22]
|
Chen, J. and Vitetta, L. (2020) Butyrate in Inflammatory Bowel Disease Therapy. Gastroenterology, 158, 1511. https://doi.org/10.1053/j.gastro.2019.08.064
|
[23]
|
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., et al. (2020) Gut Microbiota and Human NAFLD: Disentangling Microbial Signatures from Metabolic Disorders. Nature Reviews Gastroenterology & Hepatology, 17, 279-297. https://doi.org/10.1038/s41575-020-0269-9
|
[24]
|
Zhai, Q., Wu, H., Zheng, S., et al. (2023) Association between Gut Microbiota and NAFLD/NASH: A Bidirectional Two-Sample Mendelian Randomization Study. Frontiers in Cellular and Infection Microbiology, 13, Article 1294826. https://doi.org/10.3389/fcimb.2023.1294826
|
[25]
|
Schwimmer, J.B., Johnson, J.S., Angeles, J.E., et al. (2019) Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children with Nonalcoholic Fatty Liver Disease. Gastroenterology, 157, 1109-1122. https://doi.org/10.1053/j.gastro.2019.06.028
|
[26]
|
Gómez-Pérez, A.M., Ruiz-Limón, P., Salas-Salvadó, J., et al. (2023) Gut Microbiota in Nonalcoholic Fatty Liver Disease: A PREDIMED-Plus Trial Sub Analysis. Gut Microbes, 15, Article 2223339. https://doi.org/10.1080/19490976.2023.2223339
|
[27]
|
Boursier, J., Mueller, O., Barret, M., et al. (2016) The Severity of NAFLD Is Associated with Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota. Hepatology, 63, 764-775. https://doi.org/10.1002/hep.28356
|
[28]
|
Son, G., Kremer, M. and Hines, I.N. (2010) Contribution of Gut Bacteria to Liver Pathobiology. Gastroenterology Research and Practice, 2010, Article ID: 453563. https://doi.org/10.1155/2010/453563
|
[29]
|
Chiu, C.C., Ching, Y.H., Li, Y.P., et al. (2017) Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients, 9, Article 1220. https://doi.org/10.3390/nu9111220
|
[30]
|
Campo, L., Eiseler, S., Apfel, T., et al. (2019) Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. Journal of Clinical and Translational Hepatology, 7, 56-60. https://doi.org/10.14218/JCTH.2018.00008
|
[31]
|
Baumann, A., Jin, C.J., Brandt, A., et al. (2020) Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis. Nutrients, 12, Article 951. https://doi.org/10.3390/nu12040951
|
[32]
|
Pyo, J.H., Kim, T.J., Lee, H., et al. (2021) Proton Pump Inhibitors Use and the Risk of Fatty Liver Disease: A Nationwide Cohort Study. Journal of Gastroenterology and Hepatology, 36, 1235-1243. https://doi.org/10.1111/jgh.15236
|
[33]
|
Imperatore, N., Tortora, R., Testa, A., et al. (2018) Proton Pump Inhibitors as Risk Factor for Metabolic Syndrome and Hepatic Steatosis in Coeliac Disease Patients on Gluten-Free Diet. Journal of Gastroenterology, 53, 507-516. https://doi.org/10.1007/s00535-017-1381-7
|
[34]
|
Huang, H., Liu, Z., Guo, Y., et al. (2023) Long-Term Use of Proton Pump Inhibitors Is Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 58, 289-296. https://journals.lww.com/10.1097/MCG.0000000000001847 https://doi.org/10.1097/MCG.0000000000001847
|
[35]
|
Llorente, C., Jepsen, P., Inamine, T., et al. (2017) Gastric Acid Suppression Promotes Alcoholic Liver Disease by Inducing Overgrowth of Intestinal Enterococcus. Nature Communications, 8, Article No. 837. https://doi.org/10.1038/s41467-017-00796-x
|
[36]
|
Saad, M.J.A., Santos, A. and Prada, P.O. (2016) Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. Physiology, 31, 283-293. https://doi.org/10.1152/physiol.00041.2015
|
[37]
|
Tsukumo, D.M., Carvalho, B.M., Carvalho Filho, M.A., et al. (2015) Translational Research into Gut Microbiota: New Horizons on Obesity Treatment: Updated 2014. Archives of Endocrinology and Metabolism, 59, 154-160. https://doi.org/10.1590/2359-3997000000029
|
[38]
|
Jiao, N., Baker, S.S., Nugent, C.A., et al. (2018) Gut Microbiome May Contribute to Insulin Resistance and Systemic Inflammation in Obese Rodents: A Meta-Analysis. Physiological Genomics, 50, 244-254. https://doi.org/10.1152/physiolgenomics.00114.2017
|
[39]
|
Zhi, C., Huang, J., Wang, J., et al. (2019) Connection between Gut Microbiome and the Development of Obesity. European Journal of Clinical Microbiology & Infectious Diseases, 38, 1987-1998. https://doi.org/10.1007/s10096-019-03623-x
|
[40]
|
Assalin, H.B., De Almeida, K.C.G., Guadagnini, D., et al. (2022) Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver. International Journal of Molecular Sciences, 23, Article 13766. https://doi.org/10.3390/ijms232213766
|
[41]
|
Natividad, J.M., Lamas, B., Pham, H.P., et al. (2018) Bilophila wadsworthia Aggravates High Fat Diet Induced Metabolic Dysfunctions in Mice. Nature Communications, 9, Article No. 2802. https://doi.org/10.1038/s41467-018-05249-7
|
[42]
|
Brun, P., Castagliuolo, I., Di Leo, V., et al. (2007) Increased Intestinal Permeability in Obese Mice: New Evidence in the Pathogenesis of Nonalcoholic Steatohepatitis. American Journal of Physiology. American Journal of Physiology-Gastrointestinal and Liver Physiology, 292, G518-G525. https://doi.org/10.1152/ajpgi.00024.2006
|
[43]
|
Miele, L., Valenza, V., La Torre, G., et al. (2009) Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease. Hepatology, 49, 1877-1887. https://doi.org/10.1002/hep.22848
|
[44]
|
Sharifnia, T., Antoun, J., Verriere, T.G.C., et al. (2015) Hepatic TLR4 Signaling in Obese NAFLD. American Journal of Physiology-Gastrointestinal and Liver Physiology, 309, G270-G278. https://doi.org/10.1152/ajpgi.00304.2014
|
[45]
|
Kolodziejczyk, A.A., Zheng, D., Shibolet, O., et al. (2019) The Role of the Microbiome in NAFLD and NASH. EMBO Molecular Medicine, 11, e9302. https://doi.org/10.15252/emmm.201809302
|
[46]
|
Seki, E., De Minicis, S., Osterreicher, C.H., et al. (2007) TLR4 Enhances TGF-β Signaling and Hepatic Fibrosis. Nature Medicine, 13, 1324-1332. https://doi.org/10.1038/nm1663
|